Atrial Fibrillation

The risk of severe CV events, including leading to death, was greatest in the first week following an exacerbation but remained significantly elevated 1 year later.

The 10 most important take-homes from the 2023 ACC/AHA AF guidelines are summarized in this Guideline Topline, an at-a-glance preview for primary care.

The revised guidance classifies AF into 4 stages, emphasizes prevention and aggressive rhythm control, and upgrades recommendations for catheter ablation and LAA occlusion.

The novel oral anticoagulant is one in a class of agents for prevention of AF-related stroke that shows promise to reduce bleeding risk.

The AZALEA-TIMI 71 trial was stopped early due to an "overwhelming reduction" in a composite endpoint of major bleeding events compared to rivaroxaban standard of care.

Your daily dose of clinical news you may have missed.

Atrial fibrillation prevalence is rising across socioeconomic strata globally, the new analysis finds, with effects of BMI, ETOH, and sedentary behavior shifting as key drivers.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

Oldest and most frail elderly were at more than 60% greater risk of bleeding when switched from a VKA than those who remained on the traditional agent.

Internist and obesity medicine specialist Alina Elperin, MD, details the most common cardiovascular complications that she has observed in patients with obesity.

Regardless of the pattern of physical activity, it may reduce risk across a spectrum of cardiovascular diseases, say study authors. So, just do it!

Factors positively associated with a timely first OAC Rx among the 41.3% who received one included male sex, certain comorbidities, other current medications, and obesity.

Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.

Bayer's investigational FXIa inhibitor is currently being studied in a large-scale phase 3 development program expected to enroll more than 27 000 participants.

Statin therapy initiated within 1 year of diagnosis of atrial fibrillation reduced the risk of ischemic stroke or systemic embolism by nearly 20%.

Your daily dose of clinical news you may have missed.

More than two-thirds of patients not receiving OAC were open to beginning treatment but many of their physicians were not, according to a study of PINNACLE Registry participants.

Your daily dose of clinical news you may have missed.

EHRA 2023: Patients with AF who started statins within a year of diagnosis had reduced risks of stroke and TIA compared with those who did not start statins.

Your daily dose of clinical news you may have missed.

An Apple Watch feature designed to detect atrial fibrillation was associated with a low rate of false-positive detections and high specificity in persons with AF.

Among patients with recently detected AF, early rhythm control improved cardiovascular outcomes in patients of either sex without differences in safety.

Your daily dose of clinical news you may have missed.

Findings elaborate on the pathophysiological differences in autoimmunity and atrial fibrillation risk between men and women.

Find a compact sampling of 2022 cardiovascular disease research reviewed on Patient Care, chosen by the editorial staff.

The low rate of stroke prevention with oral anticoagulation in patients with atrial fibrillation is cause for significant concern, say investigators.

Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.

Black patients were also at significantly increased risk of stroke, bleeding, and mortality vs White patients 1 year following discharge.

Your daily dose of the clinical news you may have missed.

In the absence of randomized controlled head-to-head trials comparing the 2 anticoagulants, study authors say clinicians should consider their findings when choosing treatment.